(CercleFinance.com) – During a last-minute presentation at the 31st Congress of the European Academy of Dermatology and Venereology (EADV), Novartis announces positive results from two pivotal phase III studies (SUNSHINE and SUNRISE ) on his Cosentyx.
The product demonstrated superior efficacy over placebo with statistically significant improvement in common clinical signs and symptoms of moderate to severe hidradenitis suppurativa, with a favorable safety profile.
Data from these trials have been submitted to health authorities in Europe and are expected to be submitted in the United States by the end of the year. A chronic, inflammatory skin condition, hidradenitis suppurativa affects up to one in 100 people worldwide.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
